Dr. Ernest Spitzer, CEO and Medical DirectorFor more than four decades, Cardialysis has focused exclusively on cardiovascular clinical research. Headquartered in Rotterdam, the Netherlands, it operates as both a specialised clinical research organisation (CRO) and an independent cardiovascular core laboratory provider supporting global studies in interventional cardiology and structural heart therapies.
Cardiovascular trials often involve heterogeneous patient populations, complex randomisation strategies, long-term follow-up requirements and imaging-defined endpoints. These characteristics demand close coordination between scientific evaluation and clinical trial operations.
Cardialysis addresses this requirement through an integrated operating model that connects study design, site management, imaging analysis and endpoint adjudication within a single research framework. Aligning these disciplines throughout the study lifecycle enables sponsors to generate regulatory-ready evidence while maintaining methodological discipline across large international trials.
“We are a true one-stop shop research partner for sponsors that helps them deliver high-quality evidence that advances innovative cardiovascular therapies with confidence and efficiency,” says Dr. Ernest Spitzer, CEO and medical director.
Coordinating Complex Cardiovascular Studies
What operational structure enables effective coordination across large, global cardiovascular trials?
Cardialysis’ integrated research model has supported more than 400 cardiovascular trials involving over 200,000 patients across a global network of more than 1,400 investigational sites.
The engagement begins with sponsors at the earliest stages of trial design. Multidisciplinary teams—including cardiologists, imaging specialists, statisticians and clinical trial experts—collaborate with sponsors to define endpoints, imaging protocols and statistical frameworks tailored to each study.
The process then progresses through site feasibility assessments and investigator selection from the organisation’s global research network. Regulatory submissions, contracts and training are coordinated through centralised project teams to accelerate site activation.
We are a true one-stop shop research partner for sponsors that helps them deliver high-quality evidence that advances innovative cardiovascular therapies with confidence and efficiency.
Independent Core Laboratories Supporting Evidence Generation
How do centralized imaging and diagnostic core laboratories strengthen endpoint accuracy and regulatory evidence?
Alongside clinical operations, Cardialysis operates specialised cardiovascular core laboratories that centralise the analysis of imaging and diagnostic data generated during trials.
It evaluates multiple imaging modalities, including echocardiography, cardiac magnetic resonance imaging, computed tomography and electrocardiography, as well as intravascular imaging techniques such as IVUS and OCT. Analyses are conducted under cardiologist supervision using validated protocols designed to ensure consistent interpretation across participating research sites.
These imaging and functional assessments then inform clinical event committees and data safety monitoring boards, strengthening unbiased endpoint evaluation.
-
Cardialysis attributes much of its longevity to a culture designed around collaboration and specialised expertise. Cardiologists, imaging specialists, project managers and analysts operate within closely integrated teams that maintain direct access to leadership.
These imaging and functional assessments then inform clinical event committees and data safety monitoring boards, strengthening unbiased endpoint evaluation.
Human expertise remains central to this process. Experienced cardiologists, imaging specialists and clinical trialists guide endpoint selection, imaging protocols and methodological standards, ensuring that complex datasets are interpreted within a clinically meaningful framework.
Cardialysis’ core laboratories have evaluated more than 45,000 echocardiographic examinations and over 270,000 ECG analyses, producing high-fidelity datasets used for endpoint adjudication, regulatory submissions and scientific publications.
Biostatistics teams analyse the resulting clinical and imaging datasets to generate statistically robust conclusions, while medical writing specialists translate these findings into regulatory dossiers and peer-reviewed manuscripts. Through this coordinated approach, sponsors can move promising cardiovascular therapies through development programmes more efficiently. Integrated execution can shorten development timelines by 20 to 30 percent while maintaining rigorous scientific standards.
Maintaining Discipline Under Global Regulatory Oversight
What regulatory and quality frameworks ensure compliance and consistency across international cardiovascular trials?
Large cardiovascular trials operate within demanding regulatory environments overseen by agencies such as the European Medicines Agency, the U.S. Food and Drug Administration and Japan’s PMDA. Cardialysis supports compliance through structured operational controls embedded throughout the research lifecycle.
Standard operating procedures guide trial activities from protocol development and investigator training to data collection and endpoint adjudication. Imaging analyses follow validated protocols supported by inter-observer and intra-observer variability testing, while phantom validation procedures confirm measurement calibration across imaging systems.
The organisation’s data infrastructure complies with ISO 14155 Good Clinical Practice standards, ISO 27001 information security frameworks, Good Clinical Laboratory Practice requirements and FDA 21 CFR Part 11 regulations governing electronic records.
Also incorporated are endpoint definitions developed by the Academic Research Consortium (ARC), an international collaboration focused on harmonising cardiovascular trial outcomes. Cardialysis has contributed to ARC initiatives since 2006, supporting standardised definitions for clinical events such as myocardial infarction, stroke and device-related complications. These frameworks ensure that findings remain comparable across institutions, regions and regulatory environments.
Delivering Measurable Impact in Cardiovascular Research
How has Cardialysis contributed to landmark cardiovascular trials and measurable clinical outcomes?
An integrated research model has supported several landmark cardiovascular studies that have shaped clinical practice. Examples include the BENESTENT trial, the SYNTAX programme and large international trials such as GLOBAL LEADERS and MASTER DAPT, which have influenced treatment strategies in interventional cardiology.
More recently, Cardialysis provided end-to-end CRO services for the EMPIRE I study, a multicentre investigation evaluating the ALLEGRA transcatheter heart valve delivered through the IMPERIA system. Conducted across 11 European centres, the trial enrolled 137 patients with severe aortic stenosis or failing surgical bioprostheses.
Trial design, regulatory submissions, project management and clinical monitoring were conducted, while its echocardiography core laboratory delivered centralised analysis of haemodynamic parameters such as valve gradients and paravalvular leakage. The resulting dataset supported CE Mark approval of the IMPERIA delivery system in July 2025, enabling commercial introduction across European markets.
Cardialysis also collaborates with academic research networks, including the European Cardiovascular Research Institute (ECRI), supporting investigator-initiated studies that advance cardiovascular science.
Several of its programmes are now contributing to the next generation of cardiovascular evidence. Three major studies—OPTIMAL, IVUS CHIP and FAST III—were presented as late-breaking trials at the American College of Cardiology's 75th Annual Scientific Session (ACC.26) and simultaneously published in the New England Journal of Medicine, the world's leading medical journal. These trials represent some of the largest investigations in their respective domains and reflect Cardialysis’ continued involvement in large-scale multicentre cardiovascular research.
Sustaining Collaboration in Cardiovascular Science
Cardialysis attributes much of its longevity to a culture designed around collaboration and specialised expertise. Cardiologists, imaging specialists, project managers and analysts operate within closely integrated teams that maintain direct access to leadership.
This structure enables rapid responses to operational challenges and supports continuity across long-term cardiovascular research programmes. Many team members have spent years working within the same scientific domain, strengthening institutional expertise in evolving therapeutic areas.
Life Sciences Review’s recognition as the Top Cardiovascular Research Organisation in Europe 2026 reflects its sustained contribution to cardiovascular clinical science. As cardiovascular medicine continues to evolve, Cardialysis remains focused on maintaining the scientific discipline required to generate reliable evidence for the next generation of therapies.
Choosing a Cardiovascular Research Organisation
Cardiovascular research remains among the most demanding segments of clinical development. Interventional cardiology, structural heart therapies and advanced imaging endpoints require precise protocol design, consistent endpoint definitions and disciplined data handling across multiple countries. Sponsors face compressed development timelines, evolving regulatory expectations in Europe, the United States and Asia and growing scrutiny around imaging integrity and event adjudication. In this environment, the distinction between a generalist contract research provider and a cardiovascular-focused research organisation becomes consequential.
Scientific depth in trial design is a defining factor. Cardiovascular studies frequently combine complex randomisation schemes, composite endpoints and long-term follow-up. Imaging modalities such as echocardiography, cardiac MRI, CT and intravascular imaging must align tightly with protocol objectives and regulatory standards. Organisations that embed imaging scientists, statisticians and cardiologists early in protocol development reduce downstream amendments and variability. Harmonised endpoint definitions, particularly those aligned with widely adopted Academic Research Consortium frameworks, support consistent adjudication and comparability across studies. Without this discipline, site-level variability can undermine statistical power and delay submissions.
Integrated data pathways also influence execution quality. When imaging analysis, clinical event adjudication and data management operate in silos, handoffs introduce friction and inconsistency. A model that centralises independent core laboratory analysis alongside clinical operations can shorten feedback loops and maintain alignment between imaging outputs and safety reporting. Blinded assessments, inter- and intra-observer variability testing and validated electronic data capture systems are not optional features but prerequisites for defensible evidence. Regulatory agencies expect traceability, audit readiness and adherence to standards such as ISO 14155 and 21 CFR Part 11. Sponsors must assess whether a partner can demonstrate sustained compliance rather than episodic readiness.
Execution scale is another differentiator. Large cardiovascular programs often span hundreds of sites and enrol thousands of patients. Efficient feasibility assessment, coordinated multi-country submissions and experienced monitoring teams help maintain enrolment velocity. Long-standing site relationships and familiarity with interventional cardiology workflows can reduce start-up delays and protocol deviations. At the same time, methodological consistency must persist throughout multiyear follow-up, requiring stable standard operating procedures, disciplined training and centralised oversight of endpoint adjudication.
Cardialysis presents a model aligned with these expectations. It operates as a specialised cardiovascular contract research organisation, combined with independent core laboratories, offering protocol development, site management, centralised imaging analysis and biostatistics within a unified framework. Its experience spans more than four decades and hundreds of cardiovascular trials, including large interventional studies enrolling thousands of patients. Centralised expertise in echocardiography, cardiac MRI, CT and intravascular imaging is coupled with structured variability testing and standardised endpoint definitions. The organisation also reports compliance with international regulatory and data security standards, supporting audit-ready submissions across regions.
For executives evaluating a cardiovascular research partner, the question is less about breadth of service and more about depth of specialisation, continuity of methodology, and the credibility of the data under scrutiny. On those dimensions, Cardialysis stands out as a considered choice for complex cardiovascular device and drug programs that demand integrated scientific oversight and regulatory-ready evidence.
...Read more
Cardiovascular Research Info
Q1
What led to Cardialysis being recognized among top cardiovascular research organizations?
Cardialysis has built its reputation in the Cardiovascular Research Organization space through decades of focused expertise in cardiology clinical research. Founded in 1983 as a spin-off from a leading academic medical center, it combines strong scientific foundations with industry execution. Its involvement in more than 400 clinical trials and its collaboration with global pharmaceutical, biotechnology and medical device companies demonstrate its ability to deliver consistent, high-quality outcomes. This sustained contribution to advancing cardiovascular therapies underpins its recognition as a Cardiovascular Research Organization.
Q2
How does Cardialysis differentiate its approach to cardiovascular research?
A hybrid model blending academic rigor with commercial execution defines how Cardialysis operates as a Cardiovascular Research Organization. It integrates academic investigators, clinical experts and operational teams to design and execute trials with scientific depth and regulatory precision. This structure allows the company to maintain methodological strength while ensuring efficient delivery across multi-national studies. Such a balanced approach enables Cardialysis to provide Cardiovascular Research Organization services that are both innovative and reliable.
Q3
How does Cardialysis support customers throughout clinical trials?
Comprehensive trial management forms the backbone of Cardialysis’ Cardiovascular Research Organization services. It supports protocol design, site activation, clinical monitoring, data management and regulatory compliance within a unified framework. With access to over 1,400 investigational sites and extensive monitoring networks, the company ensures timely execution and consistent data quality across studies. This structured support strengthens the effectiveness of its Cardiovascular Research Organization capabilities.
Q4
What value do Cardialysis services bring to cardiovascular therapy development?
High-quality data generation and efficient trial execution define the value delivered by Cardialysis as a Cardiovascular Research Organization. Its expertise in imaging core labs and cardiovascular-specific methodologies enables accurate analysis and adjudication of clinical data. These capabilities support regulatory submissions and accelerate the development of new therapies for heart disease. By ensuring data integrity and patient safety, the company enhances the overall impact of Cardiovascular Research Organization services.
Q5
What role do expertise and infrastructure play in its services?
Specialized cardiology knowledge and advanced infrastructure are central to Cardialysis’ Cardiovascular Research Organization offerings. Its teams include experienced clinical researchers and key opinion leaders who guide study design and execution. At the same time, its core laboratory capabilities allow detailed imaging analysis and standardized evaluation across trials. This combination of expertise and infrastructure ensures that its Cardiovascular Research Organization services maintain high scientific and operational standards.
Q6
Why is Cardialysis relevant to current cardiovascular research needs?
The increasing complexity of cardiovascular therapies requires specialized research partners, and Cardialysis addresses this need as a dedicated Cardiovascular Research Organization. Its ability to manage both device and drug trials, along with its adherence to global regulatory standards, aligns with evolving industry demands. By bridging academic innovation with practical execution, the company remains closely aligned with the ongoing development of advanced cardiovascular treatments.
